The same group evaluated the efficiency of CEL_Amide LIMKi in Philadelphia chromosome-positive (BCR::ABL+) acute lymphoblastic leukemia (ALL), another subtype of leukaemia. This evidence concerns the gene BCR and acute lymphoblastic leukemia.